Document Type : Case Reports


1 Pathology Department, Faculty of Medical School, Qazvin University of Medical Sciences, Qazvin, Iran

2 Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran


Background & Objective: Coexistence of follicular epithelial and bilateral parafollicular cells derivative of carcinomas in Hashimoto’s thyroiditis and multinodular goiter background are a very rare event. Of course, all benign and malignant thyroid lesions are more prevalent in iodine deficient areas. It seems that the context for identifying the pathways influencing thyroid carcinogenesis especially coincidence form has not yet been fully understood and needs further investigation. Here, we present a case with the synchronous occurrence of papillary thyroid carcinoma and medullary thyroid carcinoma in Hashimoto’s thyroiditis and multinodular goiter background.
Case presentation: A 54-year-old woman complained of a painless mass in the anterior region of the neck. The physical examination of the patient revealed multiple nodules in her thyroid gland. In ultrasound findings, she had thyroid enlargement associated with multiple isoechoic and hypoechoic nodules in both lobes. Thyroid fine needle aspiration results suggested the diagnosis of medullary thyroid carcinoma in Hashimoto’s thyroiditis and multinodular goiter background. The frozen sections, permanent sampling, and IHC examination showed the coexistence of papillary thyroid carcinoma with bilateral medullary thyroid carcinoma in Hashimoto's disease and multinodular goiter background.
Conclusion: Studies debated about the risk factors of these pathologies including the same environmental issues or mutations in genomes and they emphasized surgeons should be aware of these lesions for diagnosis and interventional treatments. Following up the Hashimoto’s thyroiditis and multinodular goiter is required for detecting occult malignancies, and hence the right management and treatment should be performed.


Main Subjects

  1. Navya NO, Magdalene KF, Satheesh GP. Synchronous Hurthle Cell Carcinoma and Papillary Carcinoma in a Patient with Hashimoto's Thyroiditis: A Rare Case Report. Middle East J Cancer. 2014;5(4):221-4.
  2. Appetecchia M, Lauretta R, Barnabei A, Pieruzzi L, Terrenato I, Cavedon E, et al. Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study. Cancers (Basel). 2019;11(10):1516. [PMCID]       [DOI:10.3390/cancers11101516] [PMID]
  3. Fagin JA, Wells Jr SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054-67. [PMID] [PMCID] [DOI:10.1056/NEJMra1501993]
  4. Xie H, Wei B, Shen H, Gao Y, Wang L, Liu H. BRAF mutation in papillary thyroid carcinoma (PTC) and its association with clinicopathological features and systemic inflammation response index (SIRI). Am J Transl Res. 2018;10(8):2726-36.
  5. Sulaieva O, Selezniov O, Shapochka D, Belemets N, Nechay O, Chereshneva Y, et al. Hashimoto's thyroiditis attenuates progression of papillary thyroid carcinoma: deciphering immunological links. Heliyon. 2020;6(1):e03077.
  6. BAYRAK E, SERTER R. Coexistence of Papillary and Medullary Thyroid Carcinoma: A Rare Entity. Turk J Endocrinol Metab. 2020;24(2). [DOI:10.25179/tjem.2019-72499]
  7. Wells Jr SA, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. Thyroid. 2015;25(6):567-610. [DOI:10.1089/thy.2014.0335] [PMID] [PMCID]
  8. Ciampi R, Romei C, Pieruzzi L, Tacito A, Molinaro E, Agate L, et al. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland. J Endocrinol Invest. 2017;40(1):55-62. [DOI:10.1007/s40618-016-0526-5] [PMID]
  9. Molnar C, Molnar S, Bedekovics J, Mokanszki A, Gyory F, Nagy E, et al. Thyroid Carcinoma Coexisting with Hashimoto's Thyreoiditis: Clinicopathological and Molecular Characteristics Clue up Pathogenesis. Pathol Oncol Res. 2019;25(3):1191-7. [DOI:10.1007/s12253-019-00580-w] [PMID] [PMCID]
  10. Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985;312(10):601-4. [DOI:10.1056/NEJM198503073121001] [PMID]
  11. Kim KW, Park YJ, Kim EH, Park SY, Park DJ, Ahn SH, et al. Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck. 2011;33(5):691-5. [DOI:10.1002/hed.21518] [PMID]
  12. Del Rio P, Montana CM, Cozzani F, Rossini M, Loderer T, Dall'Aglio E, et al. Is there a correlation between thyroiditis and thyroid cancer? Endocrine. 2019;66(3):538-41. [DOI:10.1007/s12020-019-01935-8] [PMID]
  13. Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, von Buchwald C. Association between Hashimoto's thyroiditis and thyroid cancer in 64,628 patients. Frontiers in oncology. 2017;7:53. [DOI:10.3389/fonc.2017.00053] [PMID] [PMCID]
  14. Kabbash MM, Abdallah HA, El Shenawy AA, Mohamed MMS. The Prevalence of Thyroid Cancer in Patients with Multinodular Goiter. Egypt J Hosp Med. 2019;77(6):5906-10. [DOI:10.21608/ejhm.2019.65255]
  15. Huang BY, Hseuh C, Chao TC, Lin KJ, Lin JD. Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol. 2011;22(3):144-9. [DOI:10.1007/s12022-011-9164-9] [PMID]
  16. Degertekin CK, Yilmaz BA, Toruner FB, Kalkanci A, Iyidir OT, Fidan I, et al. Circulating Th17 cytokine levels are altered in Hashimoto's thyroiditis. Cytokine. 2016;80:13-7. [DOI:10.1016/j.cyto.2016.02.011] [PMID]
  17. Cupisti K, Raffel A, Ramp U, Wolf A, Donner A, Krausch M, et al. Synchronous occurrence of a follicular, papillary and medullary thyroid carcinoma in a recurrent goiter. Endocr J. 2005 ;52(2): 281-5. [DOI:10.1507/endocrj.52.281] [PMID]
  18. Liu X, Yan K, Lin X, Zhao L, An W, Wang C, et al. The association between BRAF V600E mutation and pathological features in PTC. Eur Arch Otorhinolaryngol. 2014;271(11):3041-52. [DOI:10.1007/s00405-013-2872-7] [PMID]